Online citations, reference lists, and bibliographies.

Managing Cancer Cachexia

E. Fabbro, A. Inui, F. Strasser
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The European Palliative Care Research Collaboration (EPCRC) has developed evidence-based recommendations for the classification and treatment of cachexia in advanced cancer patients [1]. These treatment guidelines focus on patients with advanced cancer that are likely to suffer from refractory cachexia, a very serious condition especially as many of these patients are receiving palliative care and life expectancy is often short. Little cachexia-specific research has been done on this patient group and the EPCRC treatment guidelines had to consider whether research results taken from other disease stages could be applicable for patients with advanced and incurable disease with refractory cachexia [1].
This paper references
10.1161/01.CIR.0000127956.43874.F2
Ghrelin Inhibits Proinflammatory Responses and Nuclear Factor-κB Activation in Human Endothelial Cells
W. Li (2004)
10.1007/978-88-470-0552-5
Cachexia and Wasting: A Modern Approach
G. Mantovani (2006)
10.1016/J.CLNU.2006.10.005
Cancer wasting and quality of life react to early individualized nutritional counselling!
P. Ravasco (2007)
10.1002/cncr.21315
Anorexia/cachexia‐related quality of life for children with cancer
J. Lai (2005)
10.1016/J.EJCA.2003.08.028
The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials
R. Wit (2004)
10.1093/ageing/23.1.40
Nutritional status of elderly patients during recovery from chest infection and the role of nutritional supplementation assessed by a prospective randomized single-blind trial.
J. Woo (1994)
10.6004/JNCCN.2007.0005
Are all 5-HT3 receptor antagonists the same?
Robert M McNulty (2007)
10.1007/s11864-010-0127-z
Cancer Cachexia: Traditional Therapies and Novel Molecular Mechanism-Based Approaches to Treatment
N. Kumar (2010)
10.1172/JCI21134
Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells.
V. Dixit (2004)
10.1016/S0899-9007(96)00164-5
Cracking the riddle of cancer anorexia.
A. Laviano (1996)
10.1200/JCO.1993.11.1.152
Body-composition changes in patients who gain weight while receiving megestrol acetate.
C. Loprinzi (1993)
10.1136/bmj.287.6405.1589
Benefits of supplementary tube feeding after fractured neck of femur: a randomised controlled trial.
M. Bastow (1983)
10.1002/CNCR.2820690532
Megestrol acetate in cancer anorexia and weight loss
N. S. Tchekmedyian (1992)
10.1207/S15327914NC422_1
Exercise, Cachexia, and Cancer Therapy: A Molecular Rationale
C. Ardies (2002)
10.1111/j.1532-5415.1995.tb07012.x
Predictors of 2-year mortality among older male veterans on a geriatric rehabilitation unit.
C. McMurtry (1995)
10.1016/S0899-9007(00)00449-4
Hypothalamic dopamine and serotonin in the regulation of food intake.
M. Meguid (2000)
10.1016/j.ejca.2008.02.033
Cancer cachexia: developing multimodal therapy for a multidimensional problem.
K. Fearon (2008)
10.1016/j.suc.2011.02.007
Cachexia, malnutrition, the refeeding syndrome, and lessons from Goldilocks.
J. Palesty (2011)
Pharmacologic management of anorexia/cachexia.
F. Ottery (1998)
10.1016/S1538-5442(03)00020-8
Failure to thrive.
C. Jolley (2003)
10.1200/JCO.1991.9.4.675
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
F. Roila (1991)
Basics in Clinical Nutrition
L. Sobotka (2004)
10.1002/1097-0142(19910101)67:1<33::AID-CNCR2820670107>3.0.CO;2-E
A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome
C. Moertel (1991)
10.1200/JCO.1993.11.4.762
Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.
C. Loprinzi (1993)
10.1093/jnci/83.6.449
Treatment of cancer anorexia with megestrol acetate: which is the optimal dose?
J. Feliu (1991)
10.1016/S0163-7258(97)82001-3
Pharmacology of cannabinoid CB1 and CB2 receptors.
R. Pertwee (1997)
10.1016/j.surg.2007.09.039
Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways.
Talat Waseem (2008)
10.1201/9781420048957
Pharmacotherapy of Cachexia
J. R. Nicholson (2005)
10.1080/gye.15.4.279.285
Effects of cyproheptadine clorhydrate ,a serotonin receptor antagonist ,on endocrine parameters in weight-loss related amenorrhea
A. Genazzani (2001)
10.1016/S0749-0690(18)30264-7
The role of nutrition in increased morbidity and mortality.
D. Sullivan (1995)
10.1097/00062752-200105000-00008
Hematopoietic growth factors in the older cancer patient.
L. Balducci (2001)
Primary care of the patient with cancer.
G. F. Smith (2007)
10.1164/RCCM.200604-511OC
Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats.
R. Wu (2007)
10.1200/JCO.1996.14.1.135
Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.
K. Rowland (1996)
10.1200/JCO.2003.01.095
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
P. Hesketh (2003)
Cancer cachexia: pathophysiologic aspects and treatment options.
E. Topkan (2007)
10.1093/jnci/83.9.613
Serotonin antagonists: a new class of antiemetic agents.
P. Hesketh (1991)
10.1177/109980040100200304
Cancer-Induced Fatigue and Skeletal Muscle Wasting: The Role of Exercise
S. Al-Majid (2001)
10.1097/00002820-199412000-00006
Importance of nausea
K. Jenns (1994)
10.1002/cncr.11817
Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist
P. Eisenberg (2003)
10.1053/BEEM.2002.0209
Assessment of growth.
T. J. Cole (2002)
10.1200/JCO.2007.25.18_SUPPL.9133
A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia
J. M. García (2007)
10.1053/J.GASTRO.2006.01.041
Therapeutic action of ghrelin in a mouse model of colitis.
E. Gónzalez-Rey (2006)
The starving patient: supportive care for people with cancer.
Whitman Mm (2000)
10.1002/1098-1128(200101)21:1<83::AID-MED4>3.0.CO;2-1
Cancer cachexia: a therapeutic approach.
J. Argilés (2001)
10.1517/14656566.4.12.2297
Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis
S. Grunberg (2003)
10.1023/A:1011156811739
High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials.
M. Maltoni (2001)
10.1177/014860719001400190
The refeeding syndrome: a review.
S. Solomon (1990)
10.1093/jnci/82.13.1127
Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia.
C. Loprinzi (1990)
10.1016/j.critrevonc.2011.12.003
Malnutrition in childhood cancer patients: a review on its prevalence and possible causes.
A. Brinksma (2012)
10.1002/1097-0142(19900915)66:6<1279::AID-CNCR2820660630>3.0.CO;2-R
A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer
E. Bruera (1990)
10.1007/s00520-002-0391-y
Eating-related disorders in patients with advanced cancer
F. Strasser (2002)
10.1177/082585979401000105
A Phase II Study of Delta-9-Tetrahydrocannabinol for Appetite Stimulation in Cancer-Associated Anorexia
K. Nelson (1994)
10.7326/0003-4819-64-2-328
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.
G. Bodey (1966)
10.1002/1097-0142(19900615)65:12<2657::AID-CNCR2820651210>3.0.CO;2-S
A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia
Carl G. Kardinal (1990)
10.1155/2011/410971
Refeeding Syndrome: A Literature Review
L. R. Khan (2011)
10.1111/j.1532-5415.1995.tb06390.x
Impact of nutritional status on health outcomes of nursing home residents.
D. Sullivan (1995)
10.1093/GERONA/55.12.M725
Nutritional management in long-term care: development of a clinical guideline. Council for Nutritional Strategies in Long-Term Care.
D. R. Thomas (2000)
10.1089/JPM.2006.9.409
Symptom control in palliative care--Part II: cachexia/anorexia and fatigue.
E. Del Fabbro (2006)
10.1200/jco.1997.15.1.103
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
P. Hesketh (1997)
10.1634/theoncologist.2009-0153
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.
G. Mantovani (2010)
10.1200/JCO.1994.12.1.213
The cancer anorexia-cachexia syndrome.
K. Nelson (1994)
10.1177/000992288902800901
Failure to Thrive
W. Wilcox (1989)
10.1136/gut.52.10.1479
Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial
K. Fearon (2003)
10.2165/00003495-200161040-00004
Managing Cancer-Related Anorexia/Cachexia
G. Mantovani (2012)
10.1007/s13539-010-0011-5
Ghrelin for cachexia
T. Akamizu (2010)
10.3322/canjclin.52.2.72
Cancer Anorexia‐Cachexia Syndrome: Current Issues in Research and Management
A. Inui (2002)
10.4103/0973-1075.73644
Treatment of Cachexia in Oncology
EM Tazi (2010)
10.1038/35086018
Ghrelin: An orexigenic and somatotrophic signal from the stomach
A. Inui (2001)
10.1007/s00520-001-0335-y
Antiemetic guidelines: creating a more practical treatment approach
J. Koeller (2001)
10.1111/j.1532-5415.1995.tb06097.x
Protein-energy undernutrition and the risk of mortality within one year of hospital discharge: a follow-up study.
D. Sullivan (1995)
10.1002/hed.20447
Cancer cachexia syndrome in head and neck cancer patients: Part I. Diagnosis, impact on quality of life and survival, and treatment
M. Couch (2007)
10.1007/978-88-470-0552-5_68
Treatment of Cachexia in the Elderly
S. Yeh (2006)
10.1016/0091-3057(91)90385-F
Recent clinical experience with dronabinol
T. Plasse (1991)
10.1089/104454604773840508
A chart review of cyproheptadine for stimulant-induced weight loss.
W. B. Daviss (2004)
10.1111/j.1532-5415.1994.tb04966.x
Impact of nutritional status on morbidity in a population of geriatric rehabilitation patients.
D. Sullivan (1994)
10.1038/45230
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
M. Kojima (1999)
10.3322/canjclin.56.6.323
Nutrition and Physical Activity During and After Cancer Treatment: An American Cancer Society Guide for Informed Choices
C. Doyle (2003)
10.2165/00003495-199855050-00005
A Review of the Drug Treatment of Cachexia Associated with Cancer
B. Gagnon (2012)



Semantic Scholar Logo Some data provided by SemanticScholar